Join our daily newsletter At The Bell to receive exclusive market insights
- Software specialist Vection Technologies (VR1) has signed an app-development contract with CompuGroup Medical
- Through the contract, Vection will build an eHealth mobile app for pharmacists
- Through the app, pharmacists can easily scan and identify products for efficient inventory and supply management
- The app represents an initial $50,000 in development revenue for Vection
- The two companies are busy negotiating a commercial agreement to distribute the new app
- Vection shares have remained flat today, continuing to trade for 2.5 cents each
Virtual and augmented reality specialist Vection Technologies (VR1) is taking more ground in the healthcare sector through a contract with eHealth giant CompuGroup Medical.
Vection has been signed on to create an eHealth mobile application for Studiofarma, a subsidiary of CompuGroup. eHealth refers to the healthcare sector’s use of electronics and technology — such as internet-based healthcare services or data analytics for practitioners.
Vection’s app, which represents an initial $50,000 in development revenue for the company, will target pharmacists.
Essentially, the software will let pharmacists easily scan and identify products through their smartphones. While the concept is relatively simple, Vection said the result will be error-free, real-time inventory and supply management.
The app will make use of Vection’s augmented reality (AR) tech to provide on-the-go visual realisation of product information for clients’ prescription identification and purchasing.
Essentially, the app is designed to improve efficiency among pharmacists.
According to Vection, more than one million health professionals make use of CompuGroup’s services, representing a strong market for the new eHealth app.
Studiofarma General Manager Oscar Sommaggio said as medical information becomes more readily available and customers become increasingly informed, the world of pharmacy needs to adapt to meet the more intense requirements.
“The collaboration with Vection is important for our market because it allows us to bring futuristic technological innovations to the world of pharmacies,” Oscar said.
“The questions that come to us from increasingly informed customers and the amount of information that the pharmacist must draw upon necessarily requires technological support, such as AR and VR, offered by Vection,” he explained.
With this agreement, we hope to evolve the pharmacy market by projecting it into a new dimension,” he added.
As for Vection, Managing Director Gianmarco Biagi said the CompuGroup agreement aligns with the company’s 2020 healthcare strategy.
“The agreement with CompuGroup Medical is a significant step-change in Vection’s healthcare-focused strategy, representing 1 million health professionals as users, including doctors, dentists, pharmacists and other service providers in inpatient and outpatient facilities,” Gianmarco said.
Today’s agreement comes just one week after Vection broke into the healthcare world with the announcement of FrameS Dental — a virtual reality tool designed to help train dentists.
Vection and CompuGroup are in the process of negotiating a commercial agreement for the distribution of the new app.
Vection shares have remained flat today, continuing to trade for 2.5 cents each in a $16.43 million market cap.
